Drug data last refreshed 16h ago · AI intelligence enriched 2mo ago
NEURONTIN (gabapentin) is an oral small-molecule antiepileptic agent with unknown mechanism of action, though it binds the α2δ subunit of voltage-activated calcium channels. The drug is indicated for postherpetic neuralgia and as adjunctive therapy for partial seizures, though off-label use extends to neuropathic pain conditions. Gabapentin's precise therapeutic mechanism remains unclear despite decades of clinical use.
As a mature product approaching loss of exclusivity with moderate competitive pressure (30/100), roles will focus on defensive positioning and cost management rather than growth initiatives.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Abuse Potential of Gabapentin Taken Orally Concomitantly With Oxycodone Hydrochloride in Healthy, Non-Drug-Dependent, Recreational Opioid Users
Abuse Potential of Oral Gabapentin in Healthy, Non-Drug-Dependent Individuals With Recreational Sedative Drug Use Experience
High-dose Prophylactic Gabapentin (HOPE) vs. Placebo to Prevent Opioid Use for Oral Mucositis Pain During Concurrent Chemoradiation for Head and Neck Cancer
Study Evaluating the Abuse Potential of NEURONTIN® in Healthy Non-drug Dependent, Recreational Opioid Users
Evaluating the Abuse Potential of NEURONTIN® When Taken Orally in Healthy Non-drug Dependent Participants With Sedative Drug Abuse Experience
Worked on NEURONTIN at Viatris? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on NEURONTIN offers limited growth trajectory but provides stable, defensive commercial experience in a mature neuropathic pain portfolio. Roles focus on payer negotiations, generic transition planning, and channel optimization rather than launch innovation, making it ideal for professionals seeking hands-on commercial execution in a challenged market.